NO965395L - Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen - Google Patents

Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen

Info

Publication number
NO965395L
NO965395L NO965395A NO965395A NO965395L NO 965395 L NO965395 L NO 965395L NO 965395 A NO965395 A NO 965395A NO 965395 A NO965395 A NO 965395A NO 965395 L NO965395 L NO 965395L
Authority
NO
Norway
Prior art keywords
cell cycle
monoclonal antibodies
human monoclonal
glioma
antibodies specific
Prior art date
Application number
NO965395A
Other languages
English (en)
Norwegian (no)
Other versions
NO965395D0 (no
Inventor
Michael D Dan
Original Assignee
Michael D Dan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael D Dan filed Critical Michael D Dan
Publication of NO965395D0 publication Critical patent/NO965395D0/no
Publication of NO965395L publication Critical patent/NO965395L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO965395A 1994-06-21 1996-12-13 Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen NO965395L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,093 US5639863A (en) 1994-06-21 1994-06-21 Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
PCT/CA1995/000361 WO1995035374A1 (en) 1994-06-21 1995-06-16 Human monoclonal antibodies specific to cell cycle independent glioma surface antigen

Publications (2)

Publication Number Publication Date
NO965395D0 NO965395D0 (no) 1996-12-13
NO965395L true NO965395L (no) 1996-12-17

Family

ID=23004543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965395A NO965395L (no) 1994-06-21 1996-12-13 Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen

Country Status (12)

Country Link
US (1) US5639863A (ja)
EP (1) EP0766736B1 (ja)
JP (1) JPH10501411A (ja)
CN (1) CN1074458C (ja)
AT (1) ATE205532T1 (ja)
AU (1) AU686394B2 (ja)
CA (1) CA2192079C (ja)
DE (1) DE69522689T2 (ja)
MX (1) MX9605895A (ja)
NO (1) NO965395L (ja)
NZ (1) NZ288157A (ja)
WO (1) WO1995035374A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE403001T1 (de) 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
EP1007967A2 (en) * 1997-08-04 2000-06-14 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU7262700A (en) * 1999-09-07 2001-04-10 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
CA2447832C (en) * 2000-12-22 2012-09-25 Jamshid Tanha Phage display libraries of human vh fragments
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
EP2322559A3 (en) * 2002-07-04 2011-08-03 Patrys Limited Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
NZ577824A (en) * 2003-11-12 2010-10-29 Patrys Ltd Methods of identifying neoplasm-specific antibodies and uses thereof
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) * 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
DE102004015179A1 (de) * 2004-03-25 2005-10-13 Oncomab Gmbh Antigen des PM-2 Antikörpers und dessen Verwendung
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
AU2007301599B2 (en) 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
JP2010510772A (ja) * 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
AU2010210312A1 (en) * 2009-02-09 2011-08-04 Patrys Limited SAM-6 variants, target and methods of use
CN103127528B (zh) * 2012-09-14 2016-04-20 苏州大学 人类dcx基因在制备胶质瘤放疗增敏剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2035088A1 (en) * 1990-01-29 1991-07-30 Michael D. Dan Human monoclonal antibodies for brain tumor diagnosis and therapy

Also Published As

Publication number Publication date
EP0766736B1 (en) 2001-09-12
AU2709295A (en) 1996-01-15
JPH10501411A (ja) 1998-02-10
NO965395D0 (no) 1996-12-13
NZ288157A (en) 1999-09-29
MX9605895A (es) 1997-12-31
ATE205532T1 (de) 2001-09-15
CA2192079C (en) 2001-01-09
US5639863A (en) 1997-06-17
DE69522689D1 (de) 2001-10-18
EP0766736A1 (en) 1997-04-09
CN1151184A (zh) 1997-06-04
CN1074458C (zh) 2001-11-07
CA2192079A1 (en) 1995-12-28
AU686394B2 (en) 1998-02-05
DE69522689T2 (de) 2002-08-08
WO1995035374A1 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
DK69890A (da) Monoklonale antistoffer, der er reaktive med cachetin
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
EP0331034A3 (en) Functionally specific antibodies
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
ATE291620T1 (de) Mammakarzinom-assoziiertes gen
EP0278160A3 (en) Human monoclonal anti cancer antibodies, hybridoma cell lines producing them and their uses
ATE17190T1 (de) Mittel zur tumorlokalisierung und therapie mit markierten antikoerpern und antikoerperfragmenten.